Cytokinetics
CYTK · Biotechnology
$61.23
1.8%Roivant Sciences
ROIV · Biotechnology
$36.49
2.6%The short version
- Cytokinetics is the larger business, with $88.0M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 11 times as much.
- Cytokinetics grew revenue faster (376.6%, against −71.6%).
- Cytokinetics kept more of each dollar of sales as operating profit (−695.4% operating margin, against −6,235.7% operating margin).
- Cytokinetics turned more of its sales into free cash flow (−607.5% FCF margin, against −9,183.5% FCF margin).
| Latest fiscal year | CYTK · FY25 | ROIV · FY25 |
|---|---|---|
| Size | ||
| Market cap | — | $26.3B |
| Revenue | $88.0M | $8.3M |
| Free cash flow | −$535M | −$759M |
| Net income | −$785M | −$300M |
| Growth | ||
| Revenue growth | 376.6% | −71.6% |
| 5-year growth | 9.5% | −19.0% |
| Share count change | — | −4.4% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | −695.4% | −6,235.7% |
| Net margin | −891.6% | −3,629.2% |
| FCF margin | −607.5% | −9,183.5% |
| Return on capital | — | −62.6% |
| Return on equity | — | −6.5% |
| Balance sheet | ||
| Net debt | −$912M | −$4.3B |
| Net debt / EBITDA | — | — |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | — |
| Piotroski F-score | — | 1 |
FY16
CYTK $106M
ROIV —
FY17
CYTK $13.4M
ROIV —
FY18
CYTK $31.5M
ROIV —
FY19
CYTK $26.9M
ROIV —
FY20
CYTK $55.8M
ROIV $23.8M
FY21
CYTK $70.4M
ROIV $55.3M
FY22
CYTK $94.6M
ROIV $31.5M
FY23
CYTK $7.5M
ROIV $32.7M
FY24
CYTK $18.5M
ROIV $29.1M
FY25
CYTK $88.0M
ROIV $8.3M
CYTK
ROIV
FY16
CYTK 17.6%
ROIV —
FY17
CYTK −848.3%
ROIV —
FY18
CYTK −282.3%
ROIV —
FY19
CYTK −368.0%
ROIV —
FY20
CYTK −168.3%
ROIV −4,500.5%
FY21
CYTK −264.5%
ROIV −2,444.8%
FY22
CYTK −342.8%
ROIV −2,875.9%
FY23
CYTK −6,589.7%
ROIV 13,746.9%
FY24
CYTK −2,902.7%
ROIV −3,453.3%
FY25
CYTK −695.4%
ROIV −6,235.7%
CYTK
ROIV
FY16
CYTK $35.4M
ROIV —
FY17
CYTK −$105M
ROIV —
FY18
CYTK −$102M
ROIV —
FY19
CYTK −$93.5M
ROIV —
FY20
CYTK −$2.1M
ROIV −$558M
FY21
CYTK −$191M
ROIV −$695M
FY22
CYTK −$311M
ROIV −$856M
FY23
CYTK −$416M
ROIV −$767M
FY24
CYTK −$400M
ROIV −$844M
FY25
CYTK −$535M
ROIV −$759M
CYTK
ROIV
FY16
CYTK —
ROIV —
FY17
CYTK —
ROIV —
FY18
CYTK —
ROIV —
FY19
CYTK —
ROIV —
FY20
CYTK —
ROIV —
FY21
CYTK —
ROIV —
FY22
CYTK —
ROIV −286.2%
FY23
CYTK —
ROIV —
FY24
CYTK —
ROIV —
FY25
CYTK —
ROIV −62.6%
CYTK
ROIV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.